the MASH thing finally clicked for me and I want to write it down
the MASH thing finally clicked for me and I want to write it down, which sounds obvious until you try to state the evidence for it.
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.
Sent a vial to PeptideMeter because there was nothing on file. 99.3% against a claimed 98.5%. First entry for this compound in my own log.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
The endpoint vocabulary, because you cannot read this literature without it.
Resolution of steatohepatitis without worsening of fibrosis and improvement in fibrosis without worsening of steatohepatitis are the two standard composite endpoints, both scored on biopsy by pathologists against a defined system. Liver fat fraction is an imaging surrogate that correlates imperfectly with histology.
A trial can move the surrogate substantially and the histological endpoint modestly. Both results are real; they answer different questions. Anybody quoting a response rate here should say which endpoint it refers to, and most summaries do not.
[deleted]
read the histology endpoint definitions before quoting a response rate
Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.
Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to
Agreed — and the endpoint definitions are where the actual claim lives.
Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.
a liver endpoint is not a weight endpoint with better marketing
I would not read across from the obesity programmes. Different population, different endpoint, different question.
this board is small because the compound is early
dual GLP-1 and glucagon agonist, and the glucagon arm is the story
phase 2 in liver disease is a different evidence question from weight
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
the titration in the trials was slow and deliberate
Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.
- 1Phase 2 in a biopsy-confirmed population is a demanding design: recruitment…8 comments in this branch · started by u/kaia_cabrera